跳至主要内容
临床试验/NCT00437385
NCT00437385已完成1 期

Phase 1 Study: Evaluation of Three Continuation Therapies After Acute Electroconvusive Therapy (ECT) Concerning Efficacy and Cognition in Severly Depressed Patients

Charite University, Berlin, Germany1 个研究点 分布在 1 个国家目标入组 90 人开始时间: 2005年3月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
90
试验地点
1
主要终点
Score on HAMD after 6 and 12 months

研究概览

简要总结

The purpose of this study is to evaluate three different continuation treatments after acute ECT concerning efficacy and impact on cognition in severly depressed patients.

详细描述

BACKGROUND While electroconvulsive therapy (ECT) in major depression is effective, high relapse rates and cognitive effects limit its long-term use. Continuation treatment after ECT with combinations of C-ECT or psychotherapy and medication may decrease relapse rates and cognitive side effects while changing cognitive psychological variables like dysfunctional attitudes in the long-term.

CENTRAL RESEARCH QUESTIONS

  • Evaluation of the efficacy of three continuation treatments aimed at preventing relapses after acute ECT
  • Examination of the cognitive side effects and the changes of cognitive psychological variables during acute and continuation treatment

METHODS In a prospective, randomized, controlled, long-term study we assign 60 depressed ECT responder either to antidepressant treatment alone, or C-ECT plus medication, or cognitive behavioral group therapy plus medication. Depressive symptoms and cognition were assessed before, during, immediately after acute ECT and two, four, six, and 12 months during continuation therapy.

HYPOTHESES It is hypothesized that the use of combination continuation therapies after effective ECT leads to lower HAMD scores and lower relapse rates than the standard treatment with antidepressants alone after 6 months. In addition, we assume that the CBT group will establish more functional macro-patterns than the somatic treatments in the long term and will have the lowest HAMD scores and relapse rates after 1 year. With regard to the cognitive side effects, the autobiographical memory is expected to be the only specific part of memory being affected negatively by ECT in the short and long term.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Major depressive episode (unipolar)
  • Response to acute ECT (at least 50% reduction in HAMD)
  • Capacity to consent
  • Sufficient comprehension of the German language

排除标准

  • Schizophrenia, schizoaffective disorder, or other psychosis
  • Amnestic disorder, dementia, or delirium
  • Pregnancy
  • Current alcohol or substance abuse or dependence
  • CNS disease or brain injury not associated with psychotropic drug exposure
  • ECT in the past 3 months
  • Acute suicidality
  • Judiciary hospitalization

研究组 & 干预措施

1

Active Comparator

Continuation-Medication with Antidepressants (after WBS Guidelines)

干预措施: TCAs, SSRIs, NARIs, SNRIs, Lithium (Drug)

2

Experimental

Continuation-ECT with Antidepressants

干预措施: TCAs, SSRIs, NARIs, SNRIs, Lithium (Drug)

2

Experimental

Continuation-ECT with Antidepressants

干预措施: Electroconvulsive therapy (Procedure)

3

Experimental

Continuation-Psychotherapy (Cognitive Behavioral Group Psychotherapy including the "Situational Analysis" of CBASP)

干预措施: TCAs, SSRIs, NARIs, SNRIs, Lithium (Drug)

3

Experimental

Continuation-Psychotherapy (Cognitive Behavioral Group Psychotherapy including the "Situational Analysis" of CBASP)

干预措施: Cognitive behavioral group therapy (Behavioral)

结局指标

主要结局

Score on HAMD after 6 and 12 months

时间窗: 6 and 12 months after enetering continuation phase

次要结局

  • Relapse rate after 6 and 12 months(6 and 12 months after enetering continuation phase)
  • Response and remission rates after 6 and 12 months(6 and 12 months after enetering continuation phase)
  • Scores on MADRS, BDI, and CGI after 6 and 12 months(6 and 12 months after enetering continuation phase)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Eva-Lotta Brakemeier

Dr. rer. nat.

Charite University, Berlin, Germany

研究点 (1)

Loading locations...

相似试验